Biofil Chemicals & Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−15.0%−16.6%+33.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−23.4%+3.8%−30.1%
−19.3%+12.1%−43.5%
+399.4%−21.4%+26.6%
+402.9%−22.7%+51.7%
−15.9%+8.2%+49.9%
+14.8%+3.2%+5.2%
+68.6%−180.4%+2,241.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

BIOFILCHEM₹29.41

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMANGALAMVINEETLABLASAORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹47.9 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+33.3-16.6-15.0—
EBITDA Growth—-30.1+3.8-23.4—
EBIT Growth—-43.5+12.1-19.3—
Net Income Growth—+26.6-21.4+399.4—
EPS Growth—+51.7-22.7+402.9—
Total Assets Growth—+49.9+8.2-15.9—
Total Equity Growth—+5.2+3.2+14.8—
Cash from Operations Growth—+2,241.1-180.4+68.6—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.